On Thursday, the Senate voted to confirm Stephen Hahn, MD, FASTRO, chief medical executive at the University of Texas MD Anderson Cancer Center, as the 24th commissioner of the FDA.
On Thursday, the Senate voted to confirm Stephen Hahn, MD, FASTRO, chief medical executive at the University of Texas MD Anderson Cancer Center, as the 24th commissioner of the FDA. The final vote was 72 to 18.
Among those voting against confirmation were Senators Kristen Gillibrand, D-New York; Ron Wyden, D-Oregon; and Chuck Schumer, D-New York.
Hahn received a relatively speedy confirmation to lead the agency, having been nominated by President Donald Trump just last month. During the past few weeks, however, little information about has emerged about Hahn’s strategies for leading the FDA, or about his position on fostering the US market for biosimilars.
During the confirmation process, speaking before the Senate Committee on Health, Education, Labor and Pensions, Hahn said that the FDA must encourage innovation and foster competition in order to have access to “a continuously improving universe of treatments,” and pledged to work in a bipartisan manner to serve the public.
He added that Americans want action on the problem of drug pricing, voiced support for generics and biosimilars in general, and indicated that he would work with Congress to address any delays in access to treatments that arise from the upcoming March 2020 transition of insulins to regulation as biologics.
The Biosimilars Forum congratulated Hahn on his confirmation, saying in a statement that it hopes to work with him to “translate urgency into action” on the matter of developing the biosimilars market.
However, given the robust support that biosimilars enjoyed under former commissioner Scott Gottlieb, MD, stakeholders may be left wondering whether Hahn will continue to make the FDA a vocal supporter of biosimilar competition.
During his tenure at the agency, Gottlieb oversaw the release of the Biosimilar Action Plan, called on drug makers to “end the shenanigans” that block biosimilars (including the misuse of Risk Evaluation and Mitigation Strategy programs), and took aim at pay-for-delay tactics as well as rebate and contracting provisions, all of which he said were making the biosimilars market unstable.
Even after Ned Sharpless, MD, took up his post as acting commissioner after Gottlieb’s resignation, biosimilars saw steps forward, with the approval of new biosimilars and the release of the agency’s long-awaited final guidance on interchangeability.
Additionally when Admiral Brett Giroir stepped in to helm the agency between Sharpless’ departure and Hahn’s confirmation, the agency released its momentous draft guidance on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.
That guidance, which indicated that interchangeable insulins will not generally require switching studies, represented a substantial shift in the agency’s thinking; some experts told The Center for Biosimilars® that Giror’s brief tenure in the post may have made him an ideal person to try out new ideas that could accelerate biosimilar availability before the arrival of the new commissioner whose views on biosimilars are as yet unclear to stakeholders.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.